<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01480492</url>
  </required_header>
  <id_info>
    <org_study_id>HBV20111115</org_study_id>
    <secondary_id>09zr400500</secondary_id>
    <secondary_id>30972600</secondary_id>
    <nct_id>NCT01480492</nct_id>
  </id_info>
  <brief_title>Effect of Antiviral Therapy on Host Immune in Patients With Chronic Hepatitis B Virus(HBV) Infection</brief_title>
  <official_title>Study the Effect of Nucleoside on Host Immune in Patients With CHB</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cz Li</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Changhai Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      During hepatitis B virus(HBV) infection host immune plays important role.Recently there are
      many different antiviral therapy methods.Different antiviral therapy methods showed different
      effector.In order to investigate whether these antiviral therapy methods especially methods
      directly inhibit viral replication have some effect on host immune the investigators designed
      these study. The investigators want to observe the change of host immune during antiviral
      therapy in patients with chronic HBV infection, and analyze the relationship between these
      changes and the antiviral effector of these drugs.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change of programmed death-1(PD-1) level of patients with chronic HBV infection during therapy</measure>
    <time_frame>base line-4 weeks-12 weeks-24 weeks-end of therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decline of hepatitis B e antigen (HBeAg) level</measure>
    <time_frame>base line-4weeks-12weeks-24weeks-end of therapy</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>HBeAg Positive Chronic Hepatitis B Infection</condition>
  <arm_group>
    <arm_group_label>therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telbivudine</intervention_name>
    <description>600mg,1/d,one year</description>
    <arm_group_label>therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        inclusion criteria:

          -  18-65 years old

          -  chronic HBV infection

          -  HBeAg positive,HBV DNA more than 10E5 IU/mL

          -  ALT ≥2×UTL

        exclusion criteria:

          -  with liver cancer

          -  with liver failure

          -  pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>66 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wan Mo Bin, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Changhai Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Changhai Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2011</study_first_submitted>
  <study_first_submitted_qc>November 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2011</study_first_posted>
  <last_update_submitted>November 28, 2011</last_update_submitted>
  <last_update_submitted_qc>November 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Changhai Hospital</investigator_affiliation>
    <investigator_full_name>Cz Li</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>HBV</keyword>
  <keyword>Immune</keyword>
  <keyword>antiviral therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telbivudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

